nybanner

        News

        CagriSema’s clinical acceleration of weight loss in China

        On July 5, Novo Nordisk launched a phase III clinical trial of CagriSema injection in China, the purpose of which is to compare the safety and efficacy of CagriSema injection with semeglutide in obese and overweight patients in China.

        CagriSema injection is a long-acting combination therapy under development by Novo Nordisk, the main components are GLP-1 (glucagon-like peptide-1) receptor agonist smeglutide and a long-acting amylin analog cagrilintide. CagriSema injection can be administered subcutaneously once a week.

        The primary objective was to compare CagriSema (2.4 mg/2.4 mg) with semeglutide or placebo once weekly subcutaneously. Novo Nordisk has announced the results of a trial of CagriSema for the treatment of stage 2 diabetes, which proved that CagriSema's hypoglycemic effect is better than that of semeglutide, and nearly 90% of subjects have achieved the HbA1c goal.

        news11
        news12

        The data showed that in addition to the significant hypoglycemic effect, in terms of weight loss, CagriSema injection significantly outperformed semeglutide (5.1%) and cagrilintide (8.1%) with a weight loss of 15.6%.

        The innovative drug Tirzepatide is the world's first approved weekly GIP/GLP-1 receptor agonist. It combines the effects of two incretins into a single molecule that is injected once a week and is a new class of treatments for type 2 diabetes. Tirzepatide was approved by the U.S. Food and Drug Administration (FDA) in May 2022 to improve glycemic control (on a dietary basis and exercise) in adults with type 2 diabetes and is currently approved in the European Union, Japan and other countries.

        On July 5, Eli Lilly announced a phase III SURPASS-CN-MONO study on the drug clinical trial registration and information disclosure platform for the treatment of type 2 diabetes patients. SURPASS-CN-MONO is a randomized, double-blind, placebo-controlled phase III study designed to evaluate the efficacy and safety of tirzepatide monotherapy compared to placebo in people with type 2 diabetes. The study planned to include 200 patients with type 2 diabetes who were not on any antidiabetic drugs in the 90 days prior to Visit 1 (except in certain clinical situations, such as acute illness, hospitalization, or elective surgery, short-term (≤14 days) use of insulin).

        Type 2 diabetes is expected to be approved this year

        Last month, the results of a SURPASS-AP-Combo study were published May 25 in the blockbuster journal Nature Medicine. The results showed that compared with insulin glargine, Tirzepatide showed better HbA1c and weight reduction in the population of type 2 diabetes patients in the Asia-Pacific region (mainly China): HbA1c reduction of up to 2.49% and weight reduction of up to 7.2 kg (9.4%) at 40 weeks of treatment, significant improvement in blood lipids and blood pressure, and overall safety and tolerability were good.

        The Phase 3 clinical trial of SURPASS-AP-Combo is Tirzepatide's first study conducted mainly in Chinese patients with type 2 diabetes, led by Professor Ji Linong of Peking University People's Hospital. SURPASS-AP-Combo is consistent with the results of the global SURPASS series of research, which further proves that the pathophysiology of diabetes in Chinese patients is consistent with that of global patients, which is the basis for the simultaneous research and development of new drugs in China and the world, and also provides solid evidence support for giving Chinese patients the opportunity to use the latest diabetes treatment drugs and their clinical application in China as soon as possible.


        Post time: Sep-18-2023
        主站蜘蛛池模板: 久久精品国产免费观看| 好男人视频社区www在线观看| 做暧暧免费小视频| 99re66热这里只有精品17| 欧美国产日本高清不卡| 国产成人无码一区二区三区| 丰满白嫩大屁股ass| 男人肌肌捅女人肌肌视频| 国产四虎免费精品视频| 亚洲精品无码高潮喷水在线| 久碰人澡人澡人澡人澡人视频| 日本SM极度另类视频| 亚洲婷婷天堂在线综合| 青草视频免费看| 女人被男人躁到呻吟的| 亚洲国产成人av网站| 精品一区二区三区四区电影| 国产午夜精品一区二区三区不卡| 一级片在线视频| 日韩福利视频一区| 北条麻妃74部作品在线观看| 91精品国产免费久久国语蜜臀| 曰韩高清一级毛片| 国产h视频在线观看| ASS日本少妇高潮PICS| 无码不卡中文字幕av| 亚洲AV无码一区二区二三区软件| 羞羞漫画小舞被黄漫免费| 国产高清视频一区二区| 久久国产亚洲观看| 欧美性狂猛xxxxxbbbbb| 国产一卡2卡3卡四卡高清| chinesektv直男少爷| 黑人又大又硬又粗再深一点| 在线看亚洲十八禁网站| 中文字幕免费视频精品一| 日韩大乳视频中文字幕| 亚洲国产欧美在线观看| 熟妇人妻一区二区三区四区| 国产日韩在线视频| 91极品在线观看|